scholarly journals P4-362: DOMAIN-SPECIFIC COGNITIVE IMPAIRMENT AND LONGITUDINAL COGNITIVE DECLINE DIFFER IN PARKINSON'S DISEASE DEMENTIA (PDD), DEMENTIA WITH LEWY BODIES (DLB), AND ALZHEIMER'S DISEASE (AD)

2019 ◽  
Vol 15 ◽  
pp. P1438-P1438
Author(s):  
Denis Smirnov ◽  
Douglas R. Galasko ◽  
J. Vincent Filoteo ◽  
Steven D. Edland ◽  
Lawrence A. Hansen ◽  
...  
2021 ◽  
pp. 155005942199714
Author(s):  
Lucia Zinno ◽  
Anna Negrotti ◽  
Chiara Falzoi ◽  
Giovanni Messa ◽  
Matteo Goldoni ◽  
...  

Introduction. An easily accessible and inexpensive neurophysiological technique such as conventional electroencephalography may provide an accurate and generally applicable biomarker capable of differentiating dementia with Lewy bodies (DLB) from Alzheimer’s disease (AD) and Parkinson’s disease-associated dementia (PDD). Method. We carried out a retrospective visual analysis of resting-state electroencephalography (EEG) recording of 22 patients with a clinical diagnosis of 19 probable and 3 possible DLB, 22 patients with probable AD and 21 with PDD, matched for age, duration, and severity of cognitive impairment. Results. By using the grand total EEG scoring method, the total score and generalized rhythmic delta activity frontally predominant (GRDAfp) alone or, even better, coupled with a slowing of frequency of background activity (FBA) and its reduced reactivity differentiated DLB from AD at an individual level with an high accuracy similar to that obtained with quantitative EEG (qEEG). GRDAfp alone could also differentiate DLB from PDD with a similar level of diagnostic accuracy. AD differed from PDD only for a slowing of FBA. The duration and severity of cognitive impairment did not differ between DLB patients with and without GRDAfp, indicating that this abnormal EEG pattern should not be regarded as a disease progression marker. Conclusions. The findings of this investigation revalorize the role of conventional EEG in the diagnostic workup of degenerative dementias suggesting the potential inclusion of GRDAfp alone or better coupled with the slowing of FBA and its reduced reactivity, in the list of supportive diagnostic biomarkers of DLB.


2010 ◽  
Vol 2010 ◽  
pp. 1-7 ◽  
Author(s):  
Mirko Bibl ◽  
Hermann Esselmann ◽  
Piotr Lewczuk ◽  
Claudia Trenkwalder ◽  
Markus Otto ◽  
...  

We studied the diagnostic value of CSF Aβ42/tau versus low Aβ1–42% and high Aβ1–40ox% levels for differential diagnosis of Alzheimer's disease (AD) and dementia with Lewy bodies (DLB), respectively. CSF of 45 patients with AD, 15 with DLB, 21 with Parkinson's disease dementia (PDD), and 40 nondemented disease controls (NDC) was analyzed by Aβ-SDS-PAGE/immunoblot and ELISAs (Aβ42 and tau). Aβ42/tau lacked specificity in discriminating AD from DLB and PDD. Best discriminating biomarkers were Aβ1–42% and Aβ1–40ox% for AD and DLB, respectively. AD and DLB could be differentiated by both Aβ1–42% and Aβ1–40ox% with an accuracy of 80% at minimum. Thus, we consider Aβ1–42% and Aβ1–40ox% to be useful biomarkers for AD and DLB, respectively. We propose further studies on the integration of Aβ1–42% and Aβ1–40ox% into conventional assay formats. Moreover, future studies should investigate the combination of Aβ1–40ox% and CSF alpha-synuclein for the diagnosis of DLB.


2018 ◽  
Vol 265 (10) ◽  
pp. 2295-2301 ◽  
Author(s):  
Anastasia Bougea ◽  
Leonidas Stefanis ◽  
George P. Paraskevas ◽  
Evangelia Emmanouilidou ◽  
Efthimia Efthymiopoulou ◽  
...  

Brain ◽  
2006 ◽  
Vol 129 (5) ◽  
pp. 1177-1187 ◽  
Author(s):  
Mirko Bibl ◽  
Brit Mollenhauer ◽  
Hermann Esselmann ◽  
Piotr Lewczuk ◽  
Hans-Wolfgang Klafki ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document